SS Innovations International, the Indian developer behind the indigenous SSI Mantra surgical robotic system, has successfully listed its shares on the NASDAQ stock exchange. Trading under the ticker symbol ‘SSII’ commenced today, April 25, 2025. This milestone follows a year of significant financial growth for the company.

For the fiscal year ending December 31, 2024, SS Innovations International announced revenues of $20.6 million, marking a substantial 3.5-fold increase compared to the $5.9 million reported in the previous year. The company also demonstrated improved profitability, with gross margins rising considerably from 12.3 percent in 2023 to 40.9 percent.

The SSI Mantra Surgical Robotic System, clinically validated and patented by the company, has been adopted by 80 hospitals across 75 locations in India. Its reach is also expanding internationally to countries like Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka, and Ukraine, with future plans to enter the European and United States markets. To date, the SSI Mantra system has been utilized in over 3,700 surgical procedures, including more than 200 robotic cardiac surgeries. SS Innovations has also secured regulatory approval from India's CDSCO for both telesurgery and tele-proctoring, and has already conducted 16 telesurgeries, including a long-distance robotic cardiac procedure spanning 2,000 kilometers within India.